Cell Therapeutics (CTIC) rises 3.4% premarket after giving a corporate update.
Pacritinib: Top-line data from Phase 3 in myelofibrosis in H2, a second Phase 3 trial is "expected to begin enrollment imminently."
Pixuvri: Company expects to complete enrollment in Phase 3 post-marketing commitment study in relapsed B-cell non-Hodgkin lymphoma in 2015 (endpoint changed to PFS from OS).
Tosedostat: Investigator-sponsored trials to resume in Q1.
The company says "up-front payment and anticipated near-term milestones related to the Baxter collaboration will potentially allow CTI to reach regulatory submissions for pacritinib without requiring additional equity financing to fund such activities." (PR)